Litcius/Paper detail

Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial

Juan Antonio Requena-Ibáñez, Carlos G. Santos‐Gallego, Anderly Rodriguez-Cordero, Ariana P. Vargas-Delgado, Juan J. Badimón

2022Diabetes & Metabolic Syndrome Clinical Research & Reviews51 citationsDOI

Topics & Concepts

EmpagliflozinInternal medicineQuality of life (healthcare)MedicineQuality (philosophy)PhilosophyNursingEndocrinologyDiabetes mellitusEpistemologyType 2 Diabetes MellitusDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsDiabetes Management and Research
Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial | Litcius